1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Asnake, S; Kharlyngdoh, JB; Olsson, PE; Pradhan, A | 1 |
| Arsenault, G; Berg, H; Khalaf, H; Larsson, A; McCrindle, R; Olsson, PE | 1 |
2 other study(ies) available for 1,2-dibromo-4-(1,2-dibromoethyl)cyclohexane and Cancer of Prostate
| Article | Year |
|---|---|
TBECH, 1,2-dibromo-4-(1,2 dibromoethyl) cyclohexane, alters androgen receptor regulation in response to mutations associated with prostate cancer.
Topics: Androgens; Cell Line, Tumor; Cyclohexanes; Endocrine Disruptors; Flame Retardants; Humans; Male; Mutation; Prostatic Neoplasms; Receptors, Androgen | 2016 |
Diastereomers of the brominated flame retardant 1,2-dibromo-4-(1,2 dibromoethyl)cyclohexane induce androgen receptor activation in the hepg2 hepatocellular carcinoma cell line and the lncap prostate cancer cell line.
Topics: Cell Line, Tumor; Cyclohexanes; Endocrine Disruptors; Enzyme-Linked Immunosorbent Assay; Flame Retardants; Hep G2 Cells; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Stereoisomerism | 2009 |